
AbbVie and Genentech’s investigational oncology drug ABT-199 has performed well in a Phase I trial for blood cancer, according to …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

